Objective: To evaluate longitudinal serum insulin-like growth factor-I (IGF-I) in a large cohort of children and adolescents with type 1 diabetes in relation to hemoglobin A1c (HbA1c), age, diabetes duration, and body mass index (BMI), its association to height and retinopathy, and in comparison with healthy subject references.
| INTRODUCTION
Type 1 diabetes mellitus (T1DM) is characterized by loss of the insulin-producing β-cells in the pancreatic islets, and subcutaneous administration of insulin results in portal insulin deficiency, poor growth hormone (GH) receptor signaling and low-circulating insulinlike growth factor-I (IGF-I). 1, 2 Modern insulin treatment regimens cannot restore normal portal insulin 3, 4 and low-circulating IGF-I and GH hypersecretion 5 can only be normalized with experimental treatments which delivers insulin directly into the portal vein, 6 or intraperitoneally. 7, 8 Another approach that normalizes circulating IGF-I and GH, lowers hemoglobin A1c (HbA1c) and improves insulin sensitivity is intensified insulin treatment combined with a single daily IGF-I injection. 9, 10 The elevated GH secretion causes insulin resistance in children with type 1 diabetes which is particularly pronounced during puberty. 11 Consequently, insulin doses have to be increased to maintain euglycemia, resulting in tissue hyperinsulinemia. The assumption that tissue hyperinsulinemia and GH hypersecretion increase tissue IGF-I production are supported by the finding of normal linear growth in children and adolescents with type 1 diabetes, despite of their markedly subnormal circulating IGF-I. 12, 13 It is well established that increased tissue activity of IGF-I is involved in progression of nephropathy, atherosclerosis and proliferative retinopathy. [14] [15] [16] Thus, low-circulating IGF-I reflecting high-tissue IGF-I may have direct implications on the development of long-term complications. [17] [18] [19] [20] Longitudinal serum IGF-I concentrations have been studied in smaller numbers of children and adolescents with type 1 diabetes. 21 In a slightly larger study, low levels of serum IGF-I collected longitudinally from diagnosis were associated with early markers of diabetic nephropathy, supporting the concept that circulating and tissue levels of IGF-I diverge in type 1 diabetes. 22, 23 In children and adolescents with type 1, support for an association between low-serum IGF-I and retinopathy is lacking while it was reported in a mixed population of adult type 1 and 2 20 but not in adult patients with type 2.
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The establishment of diabetes related normal reference levels for serum IGF-I provide a potential tool which may facilitate clinical management of individual patients and may become a complement to
HbA1c by independently predicting the long-term outcome for children with type 1 diabetes. The formula for calculating a diabetes, sex and age related z score for a given IGF-I level is z = (y^1
| RESEARCH DESIGN AND METHODS
where y is the given IGF-I level, mean is the age and sex related mean ∛IGF-I, and SD the SD ∛IGF-I, both of the latter found in Table 1 . 5 | RESULTS
| Type 1 diabetes associated IGF-I reference values
Mean values and reference ranges (AE2 SD) for serum IGF-I according to age in girls and boys, with and without type 1 diabetes, are shown in Figure 1A (girls) and Figure 1B (boys). In boys with type 1 diabetes, a mean peak of just above 300 μg/L was observed at 15 years of age.
The mean IGF-I of the healthy controls peaked at the same age with a value approximately 140 μg/L higher. In girls with type 1 diabetes, a mean peak value of almost 350 μg/L was observed at 13 years of age. 
| IGF-I SDS and growth
In the subgroup of 84 adolescents who had reached their adult height, this adult height was not significantly different from their mid-parental height (P = .768) and the distance to mid-parental height was −0.021
SDS. IGF-I SDS was not correlated to distance to target height in SDS
(unstandardized coefficient b = 0.020, P = .822, adjusted r 2 = −0.012), or target height in SDS (unstandardized coefficient b = −0.077, P = .478, adjusted r 2 = −0.006).
| IGF-I SDS and relation to retinopathy
Of the 746 patients who had a fundus photography, 7 patients had preproliferative retinopathy (2 male and 5 female, mean age 16.5 AE 1.2 years, mean diabetes duration 11.0 AE 4.2 years, mean HbA1c 74.4 AE 9.6 mmol/mol and mean IGF-I SDS −2.27 AE 2.0, no concurrent autoimmune or other diagnosis).
Preproliferative retinopathy was significantly associated with a lower IGF-I SDS (P = .004, adjusted r 2 = 0.021) although the effect was small, while there was no association with HbA1c, Table 2 and shown to overestimate IGF-I levels compared to other assays, 30 which may suggest that the current study underestimate the severity of IGF-I deficiency in type 1 diabetes. Apart from assay differences, the lack of Tanner stage related IGF-I SDS, as well as a lower mean HbA1c, in our present study may explain this less pronounced IGF-I deficiency.
Ahmed et al 27 reported reduced IGF-I SDS in both sexes during peak height velocity, with markedly low-IGF-I SDS in late and post pubertal boys, in accordance with our findings.
Interestingly, the peak in mean IGF-I in boys with type 1 diabetes occurred at the same age as in healthy boys suggesting that the age at onset and the progression of puberty was average while girls demonstrated a 1 year earlier peak in mean IGF-I suggesting that girls with diabetes has an earlier onset and/or faster progression of puberty.
Even in patients diagnosed during the 1st years of life, complications to type 1 diabetes are rarely seen before puberty, which may reflect the more pronounced IGF-I deficiency seen from the onset of puberty. Our subjects with diabetes and preproliferative retinopathy had a markedly lower mean IGF-I SDS than the average observed in patients without. This finding supports the hypothesis that in type 1 diabetes, a low-circulating IGF-I reflects increased local tissue level of IGF-I, possibly via GH hypersecretion and tissue hyperinsulinemia.
In mice, intraocular but not systemic IGF-I has been shown to trigger the breakdown of blood-retinal barrier. 31 Furthermore, the role of IGF-I in the progression of later stages of proliferative retinopathy of the premature is well established. 32 The pathophysiology of circulat- 
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Number of subjects FIGURE 2 HbA1c, age, diabetes duration, and BMI SDS in children with type 1 diabetes correlated with their IGF-I SDS calculated from the healthy references. black squares = both genders with 95% CI; black circles = girls; black triangles = boys may in turn impact on pubertal onset/progress. In a study by Rogers et al, 28 BMI was positively correlated to IGF-I in prepubertal but not in pubertal subjects with T1DM. In studies of children without diabetes no obvious difference in IGF-I levels has been shown between obese and non-obese children and adolescents. [34] [35] [36] [37] Evaluation of circulating IGF-I levels in girls and boys with type 1 diabetes may become of interest as a compliment to HbA1c in predicting individual risk of long-term diabetic complications. Given that IGF-I levels are lowered by approximately 1 SDS depending on gender, age, BMI and metabolic control, the reported disease related reference values should be helpful in the management of individual patients. 
